Are Antiplatelet Agents Beneficial in Essential Thrombocythemia? Maybe Yes, Probably No

Chu and colleagues report a systematic review to determine the benefits and risks of treating patients with essential thrombocythemia with antiplatelet agents. The editorialist discusses the uncertainty the review uncovers and the need for high-quality trials to definitively address this important clinical question.

from #ENT-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2szZakI